NEW YORK, Jan. 15, 2015 /PRNewswire/ -- Rock Creek Pharmaceuticals Inc. (NASDAQ: RCPI) based in Sarasota, FL recently announced the extension to the deadline for listing requirements granted by NASDAQ Stock Market Inc. The Company has until April 27, 2015 to maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive days to maintain compliance with NASDAQ listing requirements. RCPI has scheduled a proxy shareholders meeting to discuss a share consolidation which will be held on February 23, 2015. Rock Creek Pharmaceuticals Inc. has also transferred listing from the NASDAQ Global Market to the NASDAQ Capital Market. The company believes the latter is better suited for smaller companies.
For a more detailed research report with analyst comments and recommendation on Rock Creek Pharmaceuticals, Inc. please follow the link. There is no cost obligation required to view analyst brief:
Copy and paste to browser may be required.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Not Financial Advice
BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.